Cancer screening aims to distinguish cancer earlier than symptoms appear. It generally consists of two steps: a positive test and negative test. Positive test considered when signs of the disease are found and negative tests considered when no signs of the disease are found. It is classified into cervical cancer screening, breast cancer screening, bowel cancer screening, lung cancer screening, pancreatic cancer screening, testicular cancer screening, endometrial cancer screening, leukemia cancer screening, kidney cancer screening, prostate cancer screening, colorectal (colon) cancer screening, pancreatic cancer, and oral cancer screening. It includes many tests for instance DNA tests, liquid biopsies tests, blood tests, urine tests, biomarkers tests, and genetic & genomic tests, other tests, or medicinal imaging. Biomarkers tests involve alpha-fetoprotein (AFP) (liver cancer), prostate-specific antigen (PSA) (Prostate cancer), anaplastic lymphoma kinase (ALK) gene (non-small cell lung cancer) and Thyroglobulin (TG) (Thyroid cancer).
According to study, “Cancer Screening Market in India (2018-2023)” some of the major companies that are currently working in the cancer screening market in India are Philips Inc., F. Hoffmann-La Roche AG, Siemens Healthineers GmbH, Johnson & Johnson Pvt Ltd., GlaxoSmithKline PLC., GE Healthcare.
Based on the techniques, the cancer screening market is segmented into microarray, polymerase chain reaction (PCR) and real-time PCR, next-generation sequencing, fluorescence in-situ hybridization, and transcription-mediated amplification. Based on the application, this market is segmented into blood screening, oncology, infectious diseases, pharmacogenomics, human leukocyte antigen typing, and coagulation etc. Additionally, based on the end-user, the market is segmented into screening laboratories, hospitals, cancer research institutes, and screening imaging centers.
Some of the key advantages are less radical treatment desired, better result, reduced mortality &morbidity, cost savings, recognition of high-risk groups & opportunities for intervention, better prognosis, and many others. Apart from the advantages some of the drawbacks are over the treatment of borderline irregularities and resource expenses of the screening system. Furthermore, some risks are unnecessary distress, radiation, increased testing, missed diagnosis, inflammatory bowel disease (IBS), obesity, Lynch syndrome, false positives and over treatments.
The National cancer control and registration program (NCRP) is a program for cancer authentic data on cancer incidence, enterprise epidemiological studies, rising human resource in cancer epidemiology and registration &helping National Cancer Control Program (NCCP) of the country in planning, evaluation, and monitoring of cancer control activities. Moreover, the Indian Cancer Society (ICS) is a cancer detection center in Mumbai, which provides cancer recognition screening facilities and funds the treatment of cancer for poor cancer patients.
The market of Indian cancer screening is primarily driven by growing middle-class population and need of more precision based medicinal technologies & methodologies, growing patient pool, increasing research & development (R&D) funding, increasing health care expenditure, growing technological advancements, increasing therapeutic products, followed by rising in the number of cancer cases, growing awareness about early detection of cancer, increasing government initiatives & regulatory authorities.
It is expected that the Indian cancer screening market will be reached at US $ 14.7 billion, at a CAGR of 13.0 %, by 2023. In the near future market will be bright because of unhealthy food habits &sedentary way of life.
To know more, click on the link below:-
Related Reports:-
https://www.kenresearch.com/healthcare/medical-devices/mea-cancer-screening-2018-2023/172428-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
